HealthEquity’s Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns.
Latest Ratings for HQY
DateFirmActionFromTo Feb 2022Deutsche BankMaintainsBuy Dec 2021JP MorganMaintainsOverweight Dec 2021Deutsche BankMaintainsBuy